Used as a key intermediate in the synthesis of tyrosine kinase inhibitors, particularly in targeted cancer therapies. It plays a role in blocking signaling pathways involved in tumor growth and progression, especially in non-small cell lung cancer and other solid tumors. Its structure enables selective binding to mutant forms of EGFR, making it valuable in developing drugs for patients with specific genetic mutations. Also investigated for improved selectivity and reduced side effects in next-generation oncology treatments.